Status:
COMPLETED
Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Migraine
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
To assess the safety and efficacy of eletriptan for the treatment of migraine in subjects who had not been adequately treated with non-steroidal antiinflammatory drugs (NSAIDs)
Eligibility Criteria
Inclusion
- Met International Headache Society diagnostic criteria for migraine with or without aura
- Expected to suffer one to six acute migraine attacks per month based on past history
- Experienced migraines for at least one year prior to entering study, and historically have not responded to NSAIDs
Exclusion
- Frequent migraine or frequent concomitant non-migrainous headache (average of \>6 attacks per month)
- Atypical migraines that consistently failed to respond to adequate medical therapy
- Migraine with prolonged aura, familial hemiplegic migraine, basilar migraine, migrainous infarction, migraine aura without headache, or migraine with acute-onset aura
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2003
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00634985
Start Date
November 1 2002
End Date
December 1 2003
Last Update
January 27 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Çapa, Istanbul, Turkey (Türkiye)
2
Pfizer Investigational Site
Gaziantep, Turkey (Türkiye)
3
Pfizer Investigational Site
Istanbul, Turkey (Türkiye)
4
Pfizer Investigational Site
Izmir, Turkey (Türkiye)